Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

NCT03938987 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Non Hodgkin Lymphoma
Relapsed Adult ALL
Relapsed Pediatric ALL

Interventions

BIOLOGICAL: autologous CD19-directed chimeric antigen receptor (CAR) T-cells

Sponsor

University of Alberta

Collaborators

[object Object]
[object Object]